Breadcrumb Trail Links

“We live in times of unprecedented financial hardship where cost is the key determinant of health decisions.”

Author of the article:

Sam Riches Members participating in the company’s Compassionate Care program can purchase the flower. /. Photo by Lumineux_Images / iStock / Getty Images Plus

Article content

Starting April 20, Cannalogue, a Toronto-based health and technology company, is offering CBD flowers starting at $ 1.96 / gram per company press release.

According to Cannalogue, this is the lowest price per gram for medical cannabis in Canada.

  1. Cannalogue is confident of convincing Health Canada to include medical cannabis in its insurance coverage program for needy groups such as low-income households.

    The cannabis company’s petition urges the government to extend insurance coverage to the prescription pot

  2. None

    Could CBD Reduce Coronavirus Symptoms? This Toronto company is ready to put these claims to the test

  3. A study published in 2019 found

    Does cannabis have a place in the hospice?

“We live in times of unprecedented financial hardship, where cost is the key determinant of health decisions,” said Dr. Mohan Cooray, President and CEO of Cannalogue, in the press release. “Due to the lack of adequate coverage, Cannalogue is doing everything it can to help our patients, and today it is a gigantic step forward in making medical cannabis affordable for all Canadians.”

Members participating in the company’s Compassionate Care program can purchase the flower. All of the products available – from flowers to oils to capsules and topical products – are made by Health Canada licensed manufacturers.

Article content

Dr. Cooray confirmed with The GrowthOp that one variety of CBD flowers will be available for $ 1.96 / gram, but a number of other products will be available for up to 50 percent off.

“More producers are coming on board and lowering prices, so we should have a lot more choice at that price,” he said, adding that Cannalogue has the “most comprehensive compassionate program in the country.”

According to the company’s website, the qualified groups include frontline workers, seniors (60 years and older), veterans, indigenous peoples, first responders, nurses and teachers, among others. Individuals with an annual income of less than $ 70,000 per year can also qualify for the program.

Last September, Cannalogue created a petition calling for national cannabis coverage and improved access for medical patients.

“These are some of the toughest times for Canadians – especially those with chronic conditions like pain or anxiety,” said Dr. Cooray at the time. “Removing the barriers preventing access to medical cannabis is the fundamental goal of Cannalogue. This petition will help us ensure that disadvantaged groups, including those below the poverty line, receive the drugs they need.”

The company was founded in 2020 and its origins go to Dr. Cooray’s graduate degree in internal medicine at McMaster University, where he first discovered the therapeutic potential of medicinal cannabis.

“When I started my practice over five years ago, I was very skeptical about the role cannabinoids could play in digestive diseases. I didn’t think this stuff worked at all, ”he told The GrowthOp last March.

However, after seeing his patients’ success in using cannabis to treat conditions such as inflammatory bowel disease, Crohn’s disease, and ulcerative colitis, he changed his mind.

“The results that I saw have been exceptional,” he said.

Article content

We apologize, but this video could not be loaded.

Subscribe to Weekend Dispensary, a new weekly newsletter from The GrowthOp.